Research Study

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration
Principal Investigator 
David Albiani

Overview

Body Locations and Systems 
Macular Degeneration
ClinicalTrials.gov# 
NCT02307682
Status 
Closed to Recruitment
Study Start/End 
Jun 1, 2015 to Feb 28, 2018
Locations 
Vancouver Community
Name/Title 
Aleksandra Kuzmanovic, Clinical Trial Coordinator
Phone 
604-875-4253
Purpose of Study 

The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.